Amid plunging stock values, Valeant Pharmaceuticals International Inc. has named Christina Ackermann as executive vice president and general counsel to lead the company through its legal and regulatory problems.
“This is a very exciting time to be joining Valeant,” Ackermann said in a press release. “The company has many attractive opportunities as well as some challenges, which I look forward to working through with my colleagues.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
